Compare JD.Com Inc (JD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs TG Therapeutics Inc — how do they compare? JD.Com Inc trades at $31.57 (market cap $44.04B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: JD.Com Inc is far larger — about 5.8× TG Therapeutics Inc's market cap, and JD.Com Inc pays a 3.13% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| JD | TGTX | |
|---|---|---|
Market Cap | $44.04B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $36.17 | $59.06 |
52-Week Low | $25.19 | $26.94 |
Enterprise Value | $30.10B | $7.84B |
Dividend Yield | 3.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $31.46, down 6.01% over 24 hours, with technical indicators showing bullish momentum despite recent pressure. The company reported strong Q1 2026 earnings of $0.74 EPS, beating expectations by 30%, while revenue grew to $1.31 trillion in 2025. Analysts maintain a bullish consensus with 32 buy ratings and a $38.00 price target, representing 21% upside potential. Recent news highlights JD's upcoming Q2 earnings report on August 13, 2026, with expectations of 618 promotion benefits.
JD presents compelling value with a P/S ratio of 0.24 and consistent earnings beats, though net margins remain thin at 1.05%. Regulatory scrutiny of the Ceconomy acquisition and competitive pressures pose risks, but institutional accumulation and bullish technicals support further upside. The stock's current level near key support at $31 offers an attractive entry point ahead of Q2 results.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
